


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-0.68%
-16.84%
XERS
Xeris Pharma
$5.48
Strengths

Trading below its fair value

Earnings are forecast to grow
XERS Price Performance
$6.82 (-19.65%)
$7.1 (-22.82%)
$9.24 (-40.69%)
$5.58 (-1.79%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Revenue increase YoY
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Trading below its fair value
Earnings are forecast to grow
XERS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
XERS Street Sentiment is extremely bullish and have positive views on the near-term outlook
XERS has Low risk level
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Dec 10, 2025
Initiate
Overweight
Barclays
Oct 31, 2025
Reiterate
Outperform
Oppenheimer
What is XERS current stock price?
What are XERS stock strengths?
What is XERS Risk Level?
What is XERS market cap and volume?
What is XERS current Stock IQ?
Should I buy XERS stock right now?
Is XERS a Strong Buy right now?
What does a 'Strong Buy' rating mean for XERS?
What does a 'Strong Sell' rating mean for XERS?
What factors influence XERS's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
XERS
Xeris Pharma
Current Price
$5.48

XERS Price Performance
$6.82 (-19.65%)
$7.1 (-22.82%)
$9.24 (-40.69%)
$5.58 (-1.79%)
XERS Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Revenue increase YoY
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Trading below its fair value
Earnings are forecast to grow
XERS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
XERS Street Sentiment is extremely bullish and have positive views on the near-term outlook
XERS has Low risk level
Average key support and resistance price levels
Overall Wall Street Rating
XERS Stock IQ
Stock Insights
Strengths

Trading below its fair value

Earnings are forecast to grow
XERS Latest Analysis
Xeris Biopharma Holdings Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript.
Wed Mar 11, 2026
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio.
Wed Mar 4, 2026
Xeris Biopharma Holdings Inc. (NASDAQ:XERS) Q4 2025 Earnings Call Transcript. Xeris Biopharma Holdings Inc. (NASDAQ:XERS) Q4 2025 Earnings Call Transcript March 2 2026 Xeris Biopharma Holdings Inc. beats earnings expectations. Reported EPS is $0.06154 expectations were $0.03. Operator: Hello everyone. Thank you for joining us and welcome to the Xeris Biopharma Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] I will now hand the call [….]
Tue Mar 3, 2026
Xeris targets over 30% revenue growth in 2026 while expanding Recorlev investment and advancing XP-8121.
Mon Mar 2, 2026
Xeris rises on 2026 revenue guidance Q4 top-line beat.
Mon Mar 2, 2026
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates. Xeris Biopharma (XERS) delivered earnings and revenue surprises of 84.62% and 5.38% respectively for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Mon Mar 2, 2026
Xeris Pharmaceuticals GAAP EPS of $0.06 beats by $0.03 revenue of $85.81M misses by $0.19M.
Mon Mar 2, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
XERS Stock trends
XERS Stock performance
XERS Stock analysis
XERS investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.